APTX Aptinyx Inc.

3.22
-0.05  -2%
Previous Close 3.27
Open 3.31
Price To Book 0.87
Market Cap 108,398,305
Shares 33,664,070
Volume 98,582
Short Ratio
Av. Daily Volume 247,869

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2019.
NYX-458
Parkinson’s Disease Cognitive Impairment (healthy volunteers)
Phase 2 data released June 10, 2019 - primary endpoint met. Additional trial to be initiated 2H 2019.
NYX-2925
Fibromyalgia
Phase 2 data released January 16, 2019 - primary endpoint not met. Additional Phase 2 trial to be initiated 2H 2019.
NYX-2925
Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Phase 2 data due 2H 2020.
NYX-783
Post-traumatic stress disorder (PTSD)

Latest News

  1. Aptinyx Represents Untapped Value, BMO Says
  2. Aptinyx Inc. (APTX) Reports Q2 Loss, Lags Revenue Estimates
  3. Aptinyx Reports Second Quarter 2019 Financial Results and Highlights
  4. The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
  5. Should You Take Comfort From Insider Transactions At Aptinyx Inc. (NASDAQ:APTX)?
  6. Aptinyx to Present at the 2019 Wedbush PacGrow Healthcare Conference
  7. Aptinyx to Report Second Quarter 2019 Financial Results on Monday, August 12, 2019
  8. Aptinyx's Shares March Higher, Can It Continue?
  9. Aptinyx Salutes Retiring Chief Scientific Officer and NMDA Receptor Drug Discovery Pioneer, Joseph Moskal
  10. Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder
  11. Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference
  12. Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
  13. Could The Aptinyx Inc. (NASDAQ:APTX) Ownership Structure Tell Us Something Useful?
  14. Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update
  15. Were Hedge Funds Right About Dumping Aptinyx Inc. (APTX) ?
  16. Aptinyx Appoints Henry Gosebruch to Its Board of Directors
  17. Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019
  18. Biotech Bets and a Goodbye from a Favorite Expert
  19. Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers
  20. Robust Analgesic Activity of Aptinyx’s NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study